Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of talabostat and pembrolizumab and to see how
well they work for the treatment of solid cancers that have spread to other places in the
body (advanced). Talabostat may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving talabostat and pembrolizumab may help
control the disease.